XLenti™ Transient Production
Optimised third generation plasmids with enhanced safety profile and increased lentiviral yield, plus our GMP banked clonal suspension HEK293 cell line.
We custom-build plasmids containing your gene of interest and our proprietary XLenti™ expression system. Our custom engineering optimises transgene expression for small scale production and proof of concept studies.
Our up- and downstream process development experts improve titre through process optimisation, then help expedite on-boarding of technologies and facilitate technology transfer.
Evaluate and License
Our optimised lentiviral packaging plamids outperform our competitors' in cell lines including our GMP banked, clonal suspension HEK293 cell line. The XLenti™ transient system is available to evaluate and license now.
Genetic medicine has experienced tremendous growth with the approval of multiple products that dramatically improve life. Lentiviral vectors are the key component for manufacturing many of these treatments. The free availability of lentiviral packaging plasmids will significantly reduce the time and cost to develop and commercialize these products.
Transient Lentiviral Production
XLenti™ 3rd generation, self-inactivating (SIN) lentivirus packaging plasmids have codon optimised promoter and packaging sequences for increased translation efficiency, tightly controlled Tet inducible VSV-G and Gag-Pol expression to eliminate its cytotoxic effect on cell growth, and low homology between expression cassettes for an improved safety profile. Our plasmids, sold as p(ALD)Lenti are also available from our technology partner Aldevron.
OXGENE’s XLenti™ plasmid system outperforms all other commercially available equivalents, including in our GMP banked, serum-free, clonal suspension HEK293 cell line. We customise this system to optimise expression of any gene of interest, or for novel/non-standard pseudotyping.
Joining forces with OXGENE in the early stages of gene or cell therapy development allows our partners to establish and optimise transient production, including validated production up to 10L scale, before transitioning to our stable packaging and producer cell lines for large scale clinical manufacture. This provides the additional regulatory advantage of using the same genetic system throughout clinical development.
Have a look at our most recent poster here.
From our experts to yours: our scientists offer ongoing and detailed technical support, so you can have complete confidence in the performance of our technologies once transferred to your own facilities.